These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 4560435

  • 1. Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase.
    Reid JL, Calne DB, Vakil SD, Allen JG, Davies CA.
    J Neurol Sci; 1972 Sep; 17(1):45-51. PubMed ID: 4560435
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.
    Fahn S.
    Neurology; 1974 May; 24(5):431-41. PubMed ID: 4857104
    [No Abstract] [Full Text] [Related]

  • 7. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R, Bartholini G, Constantinidis J, Eisenring JJ, Geissbühler F, Yanniotis G, de Ajuriaguerra J.
    Schweiz Med Wochenschr; 1973 Oct 20; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract] [Full Text] [Related]

  • 8. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
    Stammler A, Vielhaber K.
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct 20; 40(10):564-8. PubMed ID: 4565521
    [No Abstract] [Full Text] [Related]

  • 9. [Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease].
    Schneider E, Fischer PA, Jacobi P, Maxion H.
    Arch Psychiatr Nervenkr (1970); 1973 Mar 19; 217(1):95-112. PubMed ID: 4695662
    [No Abstract] [Full Text] [Related]

  • 10. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
    Court J, Kase JC, Mena I, Palacios E.
    Rev Med Chil; 1973 Jun 19; 101(6):452-5. PubMed ID: 4764560
    [No Abstract] [Full Text] [Related]

  • 11. [Treatment of Parkinson's disease with L-dopa combined with a decarboxylase inhibitor].
    Siegfried J, Klaiber R, Perret E, Ziegler WH.
    Dtsch Med Wochenschr; 1969 Dec 26; 94(52):2678-81. PubMed ID: 4903342
    [No Abstract] [Full Text] [Related]

  • 12. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R, Gaillard JM, Guggisberg M, Gauthier G, de Ajuriaguerra J.
    Presse Med (1893); 1969 Apr 05; 77(17):619-22. PubMed ID: 5785081
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.